Clinical trial
Stem Cell Transplant for Hematological Malignancy
NCT00176930 · Masonic Cancer Center, University of Minnesota, Other · Terminated
Key facts
| NCT number | NCT00176930 |
|---|---|
| Title | Stem Cell Transplant for Hematological Malignancy |
| Official title | Allogeneic Transplant for Hematological Malignancy |
| Lead sponsor | Masonic Cancer Center, University of Minnesota, Other |
| Status | Terminated |
| Study type | Interventional |
| Conditions | Leukemia, Myeloid, Chronic, AML, Lymphocytic, Acute, MDS, JMML, Hodgkin's Disease, Non-hodgkin's Lymphoma and 1 more |
| Intervention type | Biological, Drug, Radiation |
| Interventions | Stem Cell Transplant, Cyclophosphamide, Total Body Irradiation, Busulfan, Equine ATG (ATGAM), CD4+/CD25+ cells |
| Enrollment | 330 |
| Start date | Oct 1, 2001 |
| Primary completion | Dec 1, 2019 |
| Completion | Dec 1, 2019 |
| First posted | Sep 15, 2005 |
| Last update posted | Jan 22, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: